Sei Investments Co. Has $30.36 Million Holdings in GSK PLC Sponsored ADR $GSK

Key Points

• Sei Investments Co. raised its stake in GSK PLC by 4.2%, acquiring an additional 34,395 shares and bringing its total holdings to 857,605 shares valued at approximately $30.36 million.
• GSK recently declared a quarterly dividend of $0.4206, with an annualized yield of 4.3%, while the company's dividend payout ratio currently stands at 79.17%.
• Despite recent upgrades, GSK has an average rating of "Hold" from analysts, with a price target of $37.38, after posting $1.23 EPS for the last quarter, exceeding expectations.

Sei Investments Co. raised its stake in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 4.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 857,605 shares of the pharmaceutical company's stock after purchasing an additional 34,395 shares during the period. Sei Investments Co.'s holdings in GSK were worth $30,362,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Primecap Management Co. CA increased its stake in shares of GSK by 1.8% during the first quarter. Primecap Management Co. CA now owns 25,708,020 shares of the pharmaceutical company's stock worth $995,929,000 after buying an additional 446,360 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of GSK by 0.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,566,922 shares of the pharmaceutical company's stock valued at $255,914,000 after buying an additional 35,134 shares during the last quarter. Equity Investment Corp lifted its position in GSK by 5.3% during the 1st quarter. Equity Investment Corp now owns 4,174,189 shares of the pharmaceutical company's stock worth $161,708,000 after acquiring an additional 211,608 shares during the period. Dimensional Fund Advisors LP increased its stake in GSK by 0.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,598,570 shares of the pharmaceutical company's stock valued at $87,884,000 after buying an additional 18,492 shares during the period. Finally, Schonfeld Strategic Advisors LLC boosted its stake in shares of GSK by 68.2% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 2,237,034 shares of the pharmaceutical company's stock valued at $75,656,000 after buying an additional 907,068 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company's stock.

Wall Street Analysts Forecast Growth

GSK has been the topic of several research reports. Wall Street Zen raised GSK from a "hold" rating to a "buy" rating in a report on Sunday, August 3rd. Berenberg Bank reiterated a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. Finally, Hsbc Global Res raised GSK to a "strong sell" rating in a research report on Monday, April 28th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $37.38.

GSK Stock Down 0.8%

NYSE GSK traded down $0.31 during trading on Monday, reaching $39.05. The company's stock had a trading volume of 2,442,386 shares, compared to its average volume of 5,206,852. The stock has a market capitalization of $79.57 billion, a PE ratio of 18.08, a PEG ratio of 1.71 and a beta of 0.51. The business has a 50-day moving average price of $38.50 and a 200-day moving average price of $37.99. GSK PLC Sponsored ADR has a 1-year low of $31.72 and a 1-year high of $44.67. The company has a current ratio of 0.87, a quick ratio of 0.57 and a debt-to-equity ratio of 1.07.

GSK (NYSE:GSK - Get Free Report) last released its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, beating the consensus estimate of $1.12 by $0.11. The business had revenue of $10.64 billion during the quarter, compared to analysts' expectations of $7.92 billion. GSK had a net margin of 10.81% and a return on equity of 49.22%. The firm's revenue was up 1.3% on a year-over-year basis. During the same quarter last year, the company earned $0.43 earnings per share. On average, research analysts forecast that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Cuts Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 9th. Shareholders of record on Friday, August 15th will be given a dividend of $0.4206 per share. The ex-dividend date is Friday, August 15th. This represents a $1.68 annualized dividend and a dividend yield of 4.3%. GSK's payout ratio is presently 77.78%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.